



## Corrigendum

# Advances in the use of bisphosphonates in the prostate cancer setting

JP Coxon, GM Oades, KW Colston & RS Kirby

*Prostate Cancer and Prostatic Diseases* (2004) 7, 270. doi:10.1038/sj.pcan.4500758

**Correction to:** *Prostate Cancer and Prostatic Diseases* (2004) 7, 99–104. doi:10.1038/sj.pcan.4500705

Since the publication of the above paper, the authors have identified an error in the *Development of more modern bisphosphonates* section. The original sentence had the figures reversed. The corrected sentence should read:

The median time to the first skeletal event was 321 days with placebo, and 488 days for patients receiving zoledronic acid 4 mg ( $P = 0.009$ ).